The primary outcome measure was the clinical improvement of RA following the use of JAK and IL-6R inhibitors as assessed by standardized criteria, namely, ACR20 at 12 and 24 weeks, and ACR50 or ACR70 at 12 weeks. This evidence concerns the gene IL6R and rheumatoid arthritis.